Preparation and cyclodextrin assisted dissolution rate enhancement of itraconazolium dinitrate salt

References

• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. (2002). Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci, 91:1414–1422.
   PubMed Web of Science ®Google Scholar
• Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzmán HR et al.( 2003). Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc, 125:8456–8457.
   PubMed Web of Science ®Google Scholar
• Rhee YS, Park CW, Kim KJ, Chi SC, Park ES. (2007). Behavior of itraconazole and benzyl alcohol in aqueous solution containing nonionic surfactants. Arch Pharm Res, 30:240–248.
   PubMed Web of Science ®Google Scholar
• Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J et al. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, Part II. Pharm Res, 20:1047–1054.
   PubMed Web of Science ®Google Scholar
• Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche MP et al. (2005). Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci, 24:179–186.
   PubMed Web of Science ®Google Scholar
• Ye G, Wang S, Heng PW, Chen L, Wang C. (2007). Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int J Pharm, 337:80–87.
   PubMed Web of Science ®Google Scholar
• Janssens S, Roberts C, Smith EF, Van den Mooter G. (2008). Physical stability of ternary solid dispersions of itraconazole in polyethyleneglycol 6000/hydroxypropylmethylcellulose 2910 E5 blends. Int J Pharm, 355:100–107.
   PubMed Web of Science ®Google Scholar
• Matteucci ME, Hotze MA, Johnston KP, Williams RO 3rd. (2006). Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir, 22:8951–8959.
   PubMed Web of Science ®Google Scholar
• Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J et al. (2007). Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm, 339:251–260.
   PubMed Web of Science ®Google Scholar
• Chen W, Gu B, Wang H, Pan J, Lu W, Hou H. (2008). Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm, 362:133–140.
   PubMed Web of Science ®Google Scholar
• Kumar V, Wang L, Riebe M, Tung HH, Prud’homme RK. (2009). Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters. Mol Pharm, 6:1118–1124.
   PubMed Web of Science ®Google Scholar
• Kim JK, Park JS, Kim CK. (2010). Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm, 383:209–215.
   PubMed Web of Science ®Google Scholar
• Akkar A, Müller RH. (2003). Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm, 56:29–36.
   PubMed Web of Science ®Google Scholar
• Hong JY, Kim JK, Song YK, Park JS, Kim CK. (2006). A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release, 110:332–338.
   PubMed Web of Science ®Google Scholar
• Howrie DL, Ptachcinski RJ, Griffith BP, Hardesty RJ, Rosenthal JT, Burckart GJ et al. (1985). Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm, 19:425–427.
   PubMedGoogle Scholar
• Gilis PA, Conde VD, Vandecruys R, inventors; Beads having a core coated with an antifungal and a polymer. US patent 5633015. 1997.
   Google Scholar
• Tao T, Zhao Y, Wu J, Zhou B. (2009). Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement. Int J Pharm, 367:109–114.
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Oshiba M, Nadai T. (1981). Precaution on use of hydrochloride salts in pharmaceutical formulation. J Pharm Sci, 70:594–596.
   PubMed Web of Science ®Google Scholar
• Thomas E, Rubino J. Solubility, melting point and salting-out relationships in a group of secondary amine hydrochlorides. Int J Pharm. 1996;130:179–183.
   Web of Science ®Google Scholar
• Odds FC, Bossche HV. (2000). Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother, 45:371–373.
   PubMed Web of Science ®Google Scholar
• Okabayashi K, Imaji M, Osumi T, Murakami Y, Maruyama H, Kano R et al. (2009). Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. Nihon Ishinkin Gakkai Zasshi, 50:91–94.
   PubMedGoogle Scholar
• Kumar N, Shishu Kapoor, VR. Facile syntheses of novel salts of a triazole antifungal agent with enhanced solubility.. J Heterocycl Chem, in press.
   Google Scholar
• Cardoso SG, Schapoval EE. (2000). Microbiological assay for terbinafine hydrochloride in tablets and creams. Int J Pharm, 203:109–113.
   PubMed Web of Science ®Google Scholar
• Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C et al. (2000). Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol, 38:3457–3459.
   PubMed Web of Science ®Google Scholar
• Orhan DD, Ozçelik B, Ozgen S, Ergun F. (2010). Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol Res, 165:496–504.
   PubMed Web of Science ®Google Scholar
• Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48–49.
   PubMed Web of Science ®Google Scholar
• Moore JW, Flanner HH. Mathematical Comparison of dissolution profiles. Pharm Technol. 1996;20:64–74.
   Google Scholar
• Shah VP, Tsong Y, Sathe P, Liu JP. (1998). In vitro dissolution profile comparison–statistics and analysis of the similarity factor, f2. Pharm Res, 15:889–896.
   PubMed Web of Science ®Google Scholar
• Trey SM, Wicks DA, Mididoddi PK, Repka MA. (2007). Delivery of itraconazole from extruded HPC films. Drug Dev Ind Pharm, 33:727–735.
   PubMed Web of Science ®Google Scholar
• Chowdary KP, Rao SS. (2000). Investigation of dissolution enhancement of itraconazole by solid dispersion in superdisintegrants. Drug Dev Ind Pharm, 26:1207–1211.
   PubMed Web of Science ®Google Scholar
• Tsutsumi S, Iida M, Tada N, Kojima T, Ikeda Y, Moriwaki T et al. (2011). Characterization and evaluation of miconazole salts and cocrystals for improved physicochemical properties. Int J Pharm, 421:230–236.
   PubMed Web of Science ®Google Scholar
• Hassan A, Tang YM, Ayres JW. (2004). Itraconazole formation using supercritical carbon dioxide. Drug Dev Ind Pharm, 30:1029–1035.
   PubMed Web of Science ®Google Scholar
• Miller MA, Dinunzio J, Matteucci ME, Ludher BS, Williams RO, Johnston KP. (2012). Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm, 38:557–570.
   PubMed Web of Science ®Google Scholar
• Mura P, Faucci MT, Parrini PL, Furlanetto S, Pinzauti S. (1999). Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int J Pharm, 179:117–128.
   PubMed Web of Science ®Google Scholar
• Vranic E, Uzunovic A. (2010). Dissolution studies of physical mixtures of indomethacin with alpha- and gamma-cyclodextrins. Bosn J Basic Med Sci, 10:197–203.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Challa R, Ahuja A, Ali J, Khar RK. (2005). Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, 6:E329–E357.
   PubMed Web of Science ®Google Scholar